ARPA‑H cut staff tied to commercialization and operations, according to multiple sources, shedding roles meant to move funded technologies toward market. The agency confirmed layoffs but said scientific programs remain intact; roughly 20 positions were reported affected. Sources told STAT the cuts concentrated on operational and tech‑to‑market functions rather than scientific staff. ARPA‑H was set up to accelerate high‑risk, high‑reward biomedical innovations; reductions in commercialization personnel could slow translational handoffs and industry partnerships. The moves arrive as federal biomedical funding priorities and oversight evolve; prospective awardees and industry partners will watch closely for signals about ARPA‑H’s capacity to shepherd projects from lab to clinic.